-
2026 Scientific Sessions opens four days of discovery
Jazz medleys, greetings from the American Diabetes Association® chief executive officer, an address on the future of diabetes research from a senior advisor at the National Institutes of Health, and highlights of cutting-edge science from ADA Pathway scientists marked the opening of the 2026 Scientific Sessions in New Orleans.
-
Diabetes Journal symposium to explore non-classical complications of diabetes
Norbert Stefan, MD, PhD, and three other panelists will present the latest findings on how complications such as metabolic dysfunction-associated steatotic liver disease (MASLD), infections, cancer, and diastolic dysfunction are impacting individuals living with diabetes.
More 2026 Scientific Sessions News
Scientific Sessions Newsmakers
-
Symposium to examine AI’s current and near-future impact on diabetes tech
Boris Kovatchev, PhD, and other panelists will share recent developments in the application of artificial intelligence in automated insulin delivery, clinical decision-making, nutrition estimation, diabetes coaching, and more.
-
Innovation Challenge to pitch groundbreaking projects for diabetes
The Innovation Challenge returns with live presentations on Saturday from five emerging companies developing game-changing solutions to real-world problems affecting people living with diabetes, their family members, or caregivers.
-
ADA Scholars program provides immersive professional development
Over two days, 70 early-career ADA Scholars convened for a unique opportunity to engage with peers and senior leaders while participating in programming designed to support their career growth at a pivotal stage.
-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.
-
Experts to discuss the benefits of glucagon/GLP-1 receptor dual agonism gleaned from SYNCHRONIZE
Lee Kaplan, MD, PhD, and other investigators will examine the basic science underlying injectable survodutide, as well as results from two of the four studies in the SYNCHRONIZE program.
-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
Presenter Profiles
